Order Article Reprints

Bonilha I, Gomes ÉIL, Carmo HRP, Breder I, Barreto J, Breder J, Munhoz DB, Carvalho LSF, Quinaglia T, Kimura-Medorima ST, et al. Effect of Empagliflozin with or without the Addition of Evolocumab on HDL Subspecies in Individuals with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EXCEED-BHS3 Trial. International Journal of Molecular Sciences. 2024; 25(7):4108. https://doi.org/10.3390/ijms25074108

Bonilha, Isabella, Érica Ivana Lázaro Gomes, Helison R. P. Carmo, Ikaro Breder, Joaquim Barreto, Jessica Breder, Daniel B. Munhoz, Luiz Sergio F. Carvalho, Thiago Quinaglia, Sheila T. Kimura-Medorima, and et al. 2024. "Effect of Empagliflozin with or without the Addition of Evolocumab on HDL Subspecies in Individuals with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EXCEED-BHS3 Trial" International Journal of Molecular Sciences 25, no. 7: 4108. https://doi.org/10.3390/ijms25074108

Bonilha, I., Gomes, É. I. L., Carmo, H. R. P., Breder, I., Barreto, J., Breder, J., Munhoz, D. B., Carvalho, L. S. F., Quinaglia, T., Kimura-Medorima, S. T., Gossi, C. M., Zimetti, F., Nadruz, W., Zanotti, I., & Sposito, A. C., on behalf of the EXCEED-BHS3 Group. (2024). Effect of Empagliflozin with or without the Addition of Evolocumab on HDL Subspecies in Individuals with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EXCEED-BHS3 Trial. International Journal of Molecular Sciences, 25(7), 4108. https://doi.org/10.3390/ijms25074108